Apogee Therapeutics (APGE) Competitors $55.15 +1.75 (+3.28%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$56.67 +1.52 (+2.76%) As of 10/17/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock APGE vs. MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, NUVL, AXSM, and LEGNShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. Its Competitors Merus Avidity Biosciences Grifols Cytokinetics Rhythm Pharmaceuticals Abivax CRISPR Therapeutics Nuvalent Axsome Therapeutics Legend Biotech Merus (NASDAQ:MRUS) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends. Is MRUS or APGE more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Merus' net margin of -685.64%. Apogee Therapeutics' return on equity of -34.65% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Merus-685.64% -50.28% -42.00% Apogee Therapeutics N/A -34.65%-32.76% Which has better valuation & earnings, MRUS or APGE? Apogee Therapeutics has lower revenue, but higher earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$36.13M198.63-$215.33M-$5.50-17.25Apogee TherapeuticsN/AN/A-$182.15M-$4.13-13.35 Which has more risk and volatility, MRUS or APGE? Merus has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Do insiders & institutionals have more ownership in MRUS or APGE? 96.1% of Merus shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 3.7% of Merus shares are held by insiders. Comparatively, 42.8% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend MRUS or APGE? Merus currently has a consensus target price of $93.12, indicating a potential downside of 1.87%. Apogee Therapeutics has a consensus target price of $92.63, indicating a potential upside of 67.95%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 1 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.16Apogee Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Does the media favor MRUS or APGE? In the previous week, Merus had 8 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for Merus and 1 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.14 beat Merus' score of -0.02 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Apogee Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryApogee Therapeutics beats Merus on 12 of the 15 factors compared between the two stocks. Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.46B$3.39B$6.09B$10.48BDividend YieldN/A2.28%5.73%4.80%P/E Ratio-13.3522.4484.5227.09Price / SalesN/A267.64519.33179.64Price / CashN/A46.5937.1661.22Price / Book3.4610.4112.246.52Net Income-$182.15M-$52.47M$3.32B$276.75M7 Day Performance5.11%2.32%1.26%1.97%1 Month Performance43.51%11.14%6.29%2.23%1 Year Performance3.03%11.15%59.93%35.58% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics2.6985 of 5 stars$55.15+3.3%$92.63+68.0%-1.9%$2.46BN/A-13.3591MRUSMerus1.402 of 5 stars$94.270.0%$93.12-1.2%+83.4%$7.13B$56.23M-17.1437Short Interest ↓RNAAvidity Biosciences2.5493 of 5 stars$46.18-1.7%$68.32+47.9%-1.3%$6.86B$10.90M-12.97190News CoverageInsider TradeGRFSGrifols3.7638 of 5 stars$9.61-3.4%$10.30+7.2%+12.3%$6.84B$7.81B8.2123,822CYTKCytokinetics3.8489 of 5 stars$60.64+6.4%$76.64+26.4%+7.2%$6.82B$18.47M-11.89250Trending NewsInsider TradeRYTMRhythm Pharmaceuticals2.8904 of 5 stars$97.86-1.2%$106.64+9.0%+116.1%$6.58B$156.29M-32.51140News CoverageAnalyst ForecastABVXAbivax3.5043 of 5 stars$86.67+3.3%$103.29+19.2%+795.9%$6.34BN/A0.0061Short Interest ↓High Trading VolumeCRSPCRISPR Therapeutics2.2295 of 5 stars$70.19+3.6%$71.50+1.9%+43.2%$6.16B$35M-12.93460Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionGap UpNUVLNuvalent2.8066 of 5 stars$83.85-0.4%$118.89+41.8%-9.4%$6.07BN/A-17.1140Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionAXSMAxsome Therapeutics4.73 of 5 stars$119.94-0.3%$177.93+48.4%+37.1%$6.00B$495.03M-23.66380Analyst RevisionLEGNLegend Biotech3.0558 of 5 stars$31.44-1.9%$74.22+136.1%-25.8%$5.92B$627.24M-35.732,609News CoverageAnalyst Forecast Related Companies and Tools Related Companies MRUS Competitors RNA Competitors GRFS Competitors CYTK Competitors RYTM Competitors ABVX Competitors CRSP Competitors NUVL Competitors AXSM Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APGE) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APGE Stock Alerts